The vaccine that is currently used for basic immunization in China is called adenovirus-vectored neocoronavirus vaccine (AVNV). The adenovirus-vectored neo-crown vaccine is the only neo-crown vaccine approved and marketed in China that can be used in a single-dose vaccination program. The technical principle of the adenovirus-vectored neocoronavirus vaccine is to eliminate the replication-related genes in the adenovirus (human adenovirus type 5), thus preventing the virus from replicating in the human body. The gene for the new coronavirus spiking protein is then inserted into the new virus. The combined vaccine can then replicate the neocoronavirus spiking protein in the body and activate the body’s immune system to mount an immune response. At present, the protective efficacy of the adenovirus-vectored neocoronavirus vaccine is consistent with that of other inactivated vaccines and recombinant CHO cell-based vaccines. There are some adverse reactions to this vaccine, such as redness, swelling, hardness and pain at the site of vaccination, fever, fatigue, nausea, headache, muscle pain, etc. In general, no special treatment is needed. In general, no special treatment is required, but if the symptoms persist, it is necessary to contact the vaccination center for instructions on how to handle them.